https://www.marketscreener.com/quote/stock/UCB-5963/news/UCB-Rozanolixizumab-and-Zilucoplan-Phase-3-Generalized-Myasthenia-Gravis-studies-published-in-pres-43480963/?utm_source=telegram&utm_medium=social&utm_campaign=share